Capital Guardian Trust’s Rigel Pharmaceuticals RIGL Stock Holding History

Capital Guardian Trust’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-5	Closed	–	–	472
2017 Q1	$0	Hold	5	–	–	﹤0.01%	688
2016 Q4	$0	Hold	5	–	–	﹤0.01%	728
2016 Q3	$0	Hold	5	–	–	﹤0.01%	730
2016 Q2	$0	Hold	5	–	–	﹤0.01%	767
2016 Q1	$0	Hold	5	–	–	﹤0.01%	827
2015 Q4	$0	Hold	5	–	–	﹤0.01%	732
2015 Q3	$0	Hold	5	–	–	﹤0.01%	749
2015 Q2	$0	Hold	5	–	–	﹤0.01%	760
2015 Q1	$0	Hold	5	–	–	﹤0.01%	788
2014 Q4	$0	Hold	5	–	–	﹤0.01%	612
2014 Q3	$0	Hold	5	–	–	﹤0.01%	670
2014 Q2	$0	Hold	5	–	–	﹤0.01%	571
2014 Q1	$0	Hold	5	–	–	﹤0.01%	551
2013 Q4	$0	Hold	5	–	–	﹤0.01%	603
2013 Q3	$0	Hold	5	–	–	﹤0.01%	558
2013 Q2	$0	Buy	+5	New	+$227	﹤0.01%	512

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital Guardian Trust's RIGL Position: Q2 2017 in Review

Capital Guardian Trust sold out of Rigel Pharmaceuticals (RIGL) in Q2 2017, closing a stake of 5 shares.

Capital Guardian Trust first reported a position in RIGL in Q2 2013 and held it in 16 quarters. The position peaked at $0 in Q1 2017. 110 funds tracked by Wall St. Rank hold RIGL as of Q2 2017.

Capital Guardian Trust reported no remaining Rigel Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Capital Guardian Trust sold 5 Rigel Pharmaceuticals shares in Q2 2017.
Capital Guardian Trust first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 16 quarters.
Capital Guardian Trust's Rigel Pharmaceuticals position peaked at $0 in Q1 2017.
110 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2017.

Based on Capital Guardian Trust's 13F filing for Q2 2017, filed 14 Aug 2017.